ifosfamide + irinotecan

The combination of ifosfamide and irinotecan (II) is a chemotherapy regimen used primarily for the treatment of relapsed or refractory small cell lung cancer (SCLC). This combination has shown significant efficacy in phase II clinical trials with favorable toxicity profiles, particularly for patients with good performance status and sensitive disease with limited metastatic sites. ## Efficacy and Clinical Use The ifosfamide + irinotecan combination has demonstrated impressive response rates in clinical studies. In one phase II study, the response rate was 52.9% with 2 complete responses and 16 partial responses[1]. The combination has been particularly effective for patients with performance status 0-1 and sensitive cases with only one metastatic site[1]. ## Safety Profile Common toxicities associated with this combination include: - Grade 3-4 neutropenia (observed in 52.9% of patients) - Grade 3 diarrhea (observed in 5.9% of patients)[1] Despite these side effects, the overall toxicity profile is considered favorable, making it a viable option for patients with relapsed SCLC. ## Comparative Efficacy A simulated trial using reinforcement learning methodology compared the ifosfamide + irinotecan combination with topotecan (a standard treatment) in recurrent SCLC. The simulation suggested that the II combination might be associated with better overall survival compared to topotecan[6]. These findings support further testing of the II regimen versus topotecan in properly randomized clinical trials. Another study examined a triple combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support, which showed an even higher response rate of 94.4% in refractory or relapsed SCLC[2]. This suggests that ifosfamide and irinotecan can be effectively combined with other agents for enhanced efficacy, though with potentially increased toxicity. The ifosfamide + irinotecan combination represents an important treatment option for patients with relapsed or refractory SCLC, offering meaningful clinical responses with manageable toxicity.

Other names

ifosfamide and irinotecan (II)